Stock Market Reviews

PTCT (PTC Therapeutics, Inc.) News

Get the latest news, insights, and market updates on PTCT (PTC Therapeutics, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says
  PTC Therapeutics (PTCT) investors are expected to remain focused on the Sephience rollout for phenyl
  Dec 3, 2025 - $PTCT
• Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?
  PTC’s strong third quarter and breakout Sephience launch may help explain why one life-sciences fund is quietly upping its bet.
  Dec 2, 2025 - $PTCT
• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 15 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
  Dec 1, 2025 - $PTCT
• Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls
  Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls
  Dec 1, 2025 - $PTCT
• Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
  PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT),
  Dec 1, 2025 - $PTCT
• A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000
  Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains.
  Nov 29, 2025 - $PTCT
• How The Sephience Launch Is Reshaping The Story For PTC Therapeutics’s Valuation
  PTC Therapeutics’ stock narrative has shifted as analysts raise their consensus price target from $77.93 to $80.50. This reflects heightened optimism around the company’s outlook. This change comes in the wake of strong earnings results and the robust launch of Sephience, which has exceeded early sales expectations. Stay tuned to discover how you can track these evolving analyst perspectives and remain informed about future updates to PTC’s growth story. Stay updated as the Fair Value for PTC...
  Nov 29, 2025 - $PTCT
• SanDisk stock surges after S&P 500 inclusion announcement
  Investing.com -- SanDisk Corporation (NASDAQ:SNDK) stock jumped 9% in after-hours trading Monday, extending its earlier 13.3% regular session gain, after S&P Dow Jones Indices announced the flash memory maker will be added to the S&P 500 index.
  Nov 24, 2025 - $PTCT
• Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600
  S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:
  Nov 24, 2025 - $PTCT
• PTC Therapeutics to Host R&D Day
  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipeline on Dec. 2, 2025, at 9:30 a.m. EST in New York City. The event will also be webcast.
  Nov 20, 2025 - $PTCT